EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Changes in bone mineral density in patients with prostate cancer treated with androgen deprivation therapy



Changes in bone mineral density in patients with prostate cancer treated with androgen deprivation therapy



Collegium Antropologicum 29(2): 589-591



Osteoporosis is a complication of permanent androgen deprivation in men with prostate carcinoma, following either bilateral orchiectomy or treatment with GnRH agonists. The present approach to the problem of osteoporosis includes prevention, adequate follow-up and appropriate treatment as an imperative of contemporary urological and endocrinological management of these patients. Bone densitometry was performed in 18 patients who were on GnRH agonists treatment during 1-3 years. The patients under therapy were followed clinically, PSA (prostate-specific antigen) values were determined and bone scintigraphy was performed. The bone mineral density values in 13 patients indicated osteopenia, whereas in one patient the finding was compatible with osteoporosis. Four patients had normal bone mineral density findings. Bone densitometry should be performed before initiation of treatment with GnRH agonists in order to quantify the therapy-related bone loss. Prevention of development of osteoporosis and its complications depends on the assessment of pharmacological treatment in this group of patients, including e.g. bisphosphonates and possible intermittent androgen deprivation.

(PDF emailed within 1 workday: $29.90)

Accession: 048485711

Download citation: RISBibTeXText

PMID: 16417166



Related references

Bone mineral density in prostate cancer patients treated with androgen deprivation therapy; Preliminary results. European Urology Supplements 15(13): E1630-E1631, 2016

Decrease of bone mineral density in Japanese patients with non-metastatic prostate cancer treated with androgen deprivation therapy. Journal of Bone and Mineral Metabolism: -, 2018

Effects of alendronate on bone mineral density in men with prostate cancer treated with androgen deprivation therapy. Journal of Clinical Densitometry 9(4): 431-437, 2006

Androgen deprivation therapy in patients with prostate cancer and changes in bone mineral density. Journal of Bone & Mineral Research 16(Suppl 1): S243, September, 2001

Effect of androgen deprivation therapy on bone mineral density in prostate cancer patients. Asian Journal of Andrology 6(1): 75-77, 2004

Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy. Endocrine-Related Cancer 15(4): 943-952, 2008

Effect of Androgen-deprivation Therapy on Bone Mineral Density in Japanese Patients with Prostate Cancer. In Vivo 32(2): 409-412, 2018

Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients. Urology 75(5): 1131-1137, 2010

Bone mineral density, pathological fractures and bisphosphonate therapy in prostate cancer patients on androgen deprivation therapy. Endocrine Regulations 45(4): 199-204, 2012

Self-reported exercise and bone mineral density in prostate cancer patients receiving androgen deprivation therapy. Journal of the American Association of Nurse Practitioners 26(1): 40-48, 2015

Evaluation of Bone Turnover / Quality Markers and Bone Mineral Density in Prostate Cancer Patients Receiving Androgen Deprivation Therapy with or without Denosumab. Anticancer Research 37(7): 3667-3671, 2017

Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy. Urology 70(1): 122-126, 2007

Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. Journal of Urology 176(3): 972-8; Discussion 978, 2006

Effect of Androgen-Deprivation Therapy on Bone Mineral Density in Patients with Prostate Cancer: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine 8(1), 2019

Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. Journal of Urology 167(6): 2361-2367, June, 2002